authors |
Lavrador, P; Gaspar, VM; Mano, JF |
nationality |
International |
journal |
DRUG DISCOVERY TODAY |
keywords |
NF-KAPPA-B; CONTROLLED-RELEASE STRATEGIES; POSTMENOPAUSAL OSTEOPOROSIS; OSTEOBLAST DIFFERENTIATION; RHEUMATOID-ARTHRITIS; OVARIECTOMIZED RATS; SIGNALING PATHWAY; NATURAL-PRODUCTS; STEM-CELLS; MECHANISMS |
abstract |
The use of natural compounds for treating chronic bone diseases holds remarkable potential. Among these therapeutics, naringin, a flavanone glycoside, represents one of the most promising candidates owing to its multifaceted effect on bone tissues. This review provides an up-to-date overview on naringin applications in the treatment of bone disorders, such as osteoporosis and osteoarthritis, and further highlights its potential for stem cell pro-osteogenic differentiation therapies. A critical perspective on naringin clinical translation is also provided. The topic is discussed in light of recently developed biomaterial-based approaches that potentiate its bioavailability and bioactivity. Overall, the reported pro-osteogenic, antiresorptive and antiadipogenic properties establish this flavanone as an exciting candidate for application in bone tissue engineering and regenerative medicine. |
publisher |
ELSEVIER SCI LTD |
issn |
1359-6446 |
year published |
2018 |
volume |
23 |
issue |
6 |
beginning page |
1293 |
ending page |
1304 |
digital object identifier (doi) |
10.1016/j.drudis.2018.05.012 |
web of science category |
Pharmacology & Pharmacy |
subject category |
Pharmacology & Pharmacy |
unique article identifier |
WOS:000437071200015
|